ArticleDiscover oncology2025
Chemotherapy and age stratified survival outcomes in colorectal cancer based on a population analysis from the surveillance epidemiology and end results program 2010 to 2020.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe role of chemotherapy in colorectal cancer (CRC) treatment, particularly in elderly and very young patients, remains controversial. This study aims to evaluate the survival benefits of chemotherapy across different age groups in CRC patients using real-world data.
methodsWe conducted a prospective cohort study using data from the SEER database from 2010 to 2020. A total of 256,320 CRC patients were included in the final analysis. Chemotherapy status (yes/no) was the primary exposure. Outcomes included overall survival (OS), cause-specific survival, and cumulative incidence of cancer- and non-cancer-specific deaths. Statistical analyses involved multivariable Cox proportional hazards models, and competing risks models, adjusted for key demographic and clinical covariates.
resultsChemotherapy significantly improved OS in patients aged 45 years and older, with the most substantial benefit in those aged 75-84 years (hazard ratios [HR] = 0.54, 95% confidence interval [CI] = 0.52-0.56) and ≥ 85 years (HR = 0.60, 95% CI = 0.57-0.64). Patients younger than 45 years did not show a significant survival benefit (HR = 1.02, 95% CI = 0.93-1.12). Survival benefit was consistent across tumor locations and most pronounced in stage III (HR = 0.40) and stage IV (HR = 0.39) disease. Competing risks models confirmed reduced cancer-specific mortality in older age groups. Sensitivity analyses excluding early deaths further validated the robustness of these findings.
conclusionChemotherapy conferred a survival benefit in patients aged ≥ 45 years, including the very elderly, when selection was based on functional status rather than age alone, whereas no clear benefit emerged in younger patients. This association persisted after multivariable adjustment and across stage-stratified and sensitivity analyses. Given SEER's lack of regimen, timing, comorbidity, and targeted-therapy detail, cautious interpretation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.